[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,407,579
  • Shares Outstanding, K 48,722
  • Annual Sales, $ 109,790 K
  • Annual Income, $ -153,490 K
  • EBIT $ -108 M
  • EBITDA $ -110 M
  • 60-Month Beta 1.58
  • Price/Sales 13.26
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 91.60% (+1.60%)
  • Historical Volatility 72.42%
  • IV Percentile 53%
  • IV Rank 9.87%
  • IV High 367.08% on 05/27/25
  • IV Low 61.45% on 08/26/25
  • Expected Move (DTE 24) 3.40 (11.77%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 35
  • Volume Avg (30-Day) 339
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 7,453
  • Open Int (30-Day) 8,272
  • Expected Range 25.49 to 32.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.42
  • Number of Estimates 4
  • High Estimate $-0.25
  • Low Estimate $-0.61
  • Prior Year $-1.05
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.61 +27.78%
on 04/28/26
32.37 -10.75%
on 05/11/26
+2.83 (+10.86%)
since 04/22/26
3-Month
16.50 +75.09%
on 03/30/26
32.37 -10.75%
on 05/11/26
+7.82 (+37.11%)
since 02/20/26
52-Week
3.61 +701.39%
on 05/30/25
32.37 -10.75%
on 05/11/26
+24.81 (+608.09%)
since 05/22/25

Most Recent Stories

More News
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced...

URGN : 28.89 (-3.31%)
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk...

URGN : 28.89 (-3.31%)
UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 28.89 (-3.31%)
UroGen Reports ZUSDURIâ„¢ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

ZUSDURIâ„¢ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved...

URGN : 28.89 (-3.31%)
UroGen's Revenue Momentum Thesis Meets Its First Real Test Without Pipeline Updates

Barchart Research What to Expect from URGN Earnings URGN Generated May 5, 2026 Current Price $23.83 EPS Estimate $$-0.56 Consensus Rating Strong Buy Average Move 6.95% UroGen's Revenue Momentum Thesis...

URGN : 28.89 (-3.31%)
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 28.89 (-3.31%)
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 28.89 (-3.31%)
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen...

URGN : 28.89 (-3.31%)
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50 Many respondents report undergoing five or more cystoscopies,...

URGN : 28.89 (-3.31%)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 28.89 (-3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

3rd Resistance Point 31.18
2nd Resistance Point 30.69
1st Resistance Point 29.79
Last Price 28.89
1st Support Level 28.39
2nd Support Level 27.90
3rd Support Level 27.00

See More

52-Week High 32.37
Last Price 28.89
Fibonacci 61.8% 21.38
Fibonacci 50% 17.99
Fibonacci 38.2% 14.59
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.